Original Article
Prophylactic Use of Implanted Cardiac Defibrillators in Patients at High Risk for Ventricular Arrhythmias after Coronary-Artery Bypass Graft Surgery
N Engl J Med 1997; 337:1569-1575November 27, 1997
- Abstract
Background
Patients with coronary heart disease, left ventricular dysfunction, and abnormalities on signal-averaged electrocardiograms have an increased risk of sudden death. We evaluated the effect on survival of the prophylactic implantation of cardioverter–defibrillators in such patients at the time of coronary-artery bypass surgery.
Methods
Over the course of five years, 37 clinical centers screened all patients who were scheduled for elective coronary bypass surgery. Patients were eligible for the trial if they were less than 80 years old, had a left ventricular ejection fraction of less than 0.36, and had abnormalities on signal-averaged electrocardiograms. We identified 1422 eligible patients, enrolled 1055, and randomly assigned 900 to therapy with an implantable cardioverter–defibrillator (446 patients) or to the control group (454 patients). The primary end point of the study was overall mortality, and the two groups were compared in an intention-to-treat analysis.
Results
The base-line characteristics of the two groups were similar. During an average (±SD) follow-up of 32±16 months, there were 101 deaths in the defibrillator group (71 from cardiac causes) and 95 in the control group (72 from cardiac causes). The hazard ratio for death from any cause was 1.07 (95 percent confidence interval, 0.81 to 1.42; P = 0.64). There was no statistically significant interaction between defibrillator therapy and any of 10 preselected base-line covariates.
Conclusions
We found no evidence of improved survival among patients with coronary heart disease, a depressed left ventricular ejection fraction, and an abnormal signal-averaged electrocardiogram in whom a defibrillator was implanted prophylactically at the time of elective coronary bypass surgery.
Media in This Article
Figure 1
Kaplan–Meier Analysis of the Probability of Death According to Study Group.Figure 2
Kaplan–Meier Analysis of the Probability of the Discharge of a First Shock from the Implanted Cardiac Defibrillator in the Defibrillator Group.Article Activity
- Article
Many cases of sudden death are caused by sustained ventricular tachyarrhythmias. Implantable cardioverter–defibrillators accurately detect and effectively terminate ventricular tachycardia or ventricular fibrillation in laboratory and clinical settings.1,2 Observational studies document low rates of sudden death among patients treated with implanted defibrillators,3 but only recently has a benefit in terms of overall mortality been demonstrated. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators report elsewhere in this issue of the Journal 4 that patients with previous cardiac arrest or sustained ventricular tachycardia have lower mortality rates when treated with implanted cardioverter–defibrillators than when treated with either amiodarone or sotalol.
Patients who have out-of-hospital cardiac arrest have a very low probability of survival.5,6 Prevention or effective treatment of a first episode of cardiac arrest therefore remains an important goal. The prophylactic use of class I antiarrhythmic drugs in patients at high risk for sudden death after myocardial infarction increased mortality rates.7 The Multicenter Automatic Defibrillator Implantation Trial (MADIT) compared prophylaxis with an implanted defibrillator with conventional therapy (mostly amiodarone) in patients with coronary heart disease, left ventricular ejection fractions below 0.36, spontaneous unsustained ventricular tachycardia, and sustained ventricular tachycardia that could be induced during electrophysiologic study; overall mortality was strikingly reduced in the group randomly assigned to defibrillator therapy.8 Coronary bypass surgery also decreases the rate of sudden death and overall mortality among patients with left ventricular dysfunction.9,10 In the Coronary Artery Bypass Graft (CABG) Patch Trial, we tested the hypothesis that the prophylactic implantation of a cardiac defibrillator at the time of bypass surgery would further improve long-term survival in patients at high risk for sudden death who were identified on the basis of a left ventricular ejection fraction below 0.36 and abnormalities on a signal-averaged electrocardiogram. We evaluated the effect on survival of the prophylactic implantation of a cardioverter–defibrillator in a group of patients among whom there were no significant differences in the frequency of therapy with antiarrhythmic drugs, beta-blocking drugs, thoracotomy, and cardiac revascularization.11
Methods
The trial was conducted at 37 clinical centers, 35 in the United States and 2 in Germany. The protocol was approved by the institutional review board at each clinical center.
Recruitment and Randomization
Enrollment in the trial began on August 14, 1990, with a pilot study.11 In 1993, a full-scale study was launched in which the same inclusion and exclusion criteria were used. Patients of either sex who were scheduled for coronary bypass surgery were eligible if they were less than 80 years of age, had a left ventricular ejection fraction of less than 0.36, and had abnormalities on a signal-averaged electrocardiogram (duration of the filtered QRS complex, >114 msec; root-mean-square voltage in the terminal 40 msec of the QRS complex, <20 μV; or duration of the terminal filtered QRS complex at <40 μV, >38 msec). A pilot study showed that patients with an abnormal signal-averaged electrocardiogram had a mortality rate in the two years after coronary bypass surgery that was twice as high as that among patients with a normal signal-averaged electrocardiogram.11,12 The signal-averaged electrocardiogram was the most feasible marker of arrhythmia for use in identifying patients for enrollment, given the short time between hospital admission and surgery.11
Patients were excluded if they had a history of sustained ventricular tachycardia or fibrillation, diabetes mellitus with poor blood glucose control or recurrent infections, previous or concomitant aortic- or mitral-valve surgery, concomitant cerebrovascular surgery, a serum creatinine concentration greater than 3 mg per deciliter (265 mmol per liter), emergency coronary bypass surgery, a noncardiovascular condition with expected survival of less than two years, or an inability to attend follow-up visits.11 Patients were enrolled in the trial after giving written informed consent.
Two independent randomization schedules were set up for each hospital, one for patients with left ventricular ejection fractions of 0.20 or less and another for patients with left ventricular ejection fractions from 0.21 to 0.35. Patients were randomly assigned to the defibrillator or control group within randomly permuted blocks. Randomization took place in the operating room after bypass grafting had been completed and patients were on partial cardiopulmonary bypass. The attending surgeon had the option not to have a patient randomly assigned to a treatment group if he or she thought that implanting and testing a defibrillator system in that patient was too risky.11
Patients who were assigned to implanted-defibrillator therapy had an epicardial defibrillator system implanted and tested twice at 20 joules of energy. Guidant/CPI (St. Paul, Minn.) provided leads and pulse generators for the trial that were approved by the Food and Drug Administration. Most of the pulse generators implanted in the trial were committed devices (i.e., devices that deliver a shock even if the arrhythmia stops before the end of charging) that were not capable of storing electrograms.13 The trial protocol prohibited the use of antiarrhythmic drugs for asymptomatic ventricular arrhythmia and specified that patients without contraindications should be treated with aspirin.
Follow-up
All variables listed on study forms were defined in a manual of operations. All qualifying signal-averaged electrocardiograms were interpreted a second time at the core study laboratory. Quality-control procedures for the measurement of the left ventricular ejection fraction have been described elsewhere.13 Patients were scheduled for follow-up visits every three months. Those who were eligible but not enrolled or enrolled but not randomly assigned to a study group were followed for 12 months to determine their vital status and rate of rehospitalization. For this report, we obtained each patient's vital status as of April 30, 1997.
Study Design and Statistical Analysis
The trial had a two-group parallel design with 900 patients randomly assigned with equal probability to prophylaxis with an implantable cardioverter–defibrillator or to no defibrillator therapy (the control group). The design ensured that the study had a power of more than 80 percent to detect a difference of 26 percent in mortality between the groups, a difference that corresponded to a 40 percent reduction in the hazard rate for death from all causes in the defibrillator group as compared with the control group, allowing for anticipated crossovers.11 Details of the randomization scheme and adjustments that were made to sample size and follow-up have been published elsewhere.11,14 The nature of the intervention precluded the blinding of investigators or patients.
Accumulating data were reviewed by an independent Data and Safety Monitoring Board. Four interim analyses were scheduled and performed; they were based on sequential-monitoring procedures for the groups, with prospective stopping rules defined by a Lan–DeMets boundary with an O'Brien–Fleming spending function.15,16 Cumulative survival curves for each group were estimated by the Kaplan–Meier method.17 Cox proportional-hazards regression models were used to estimate hazard ratios (instantaneous relative risks).18 Log-rank tests, stratified according to ejection fraction and clinical center, were used to test hypotheses about differences between the groups. The secondary analyses reported here were also based on Cox models and examined survival after surgery and treatment interactions for prespecified subgroups. We selected 10 covariates prospectively and evaluated their interaction with the effect of implanted-defibrillator treatment on the risk of death: they were age, sex, presence or absence of heart failure, New York Heart Association (NYHA) functional class, left ventricular ejection fraction, presence or absence of diabetes mellitus, duration of the QRS complex (>100 msec or <100 msec), use of angiotensin-converting–enzyme inhibitors, use of class I or class III antiarrhythmic drugs, and use of beta-adrenergic–blocking drugs. All analyses adhered to the intention-to-treat principle.
Results
Study Sample and Comparison of the Treatment Groups
Five percent of the patients screened were excluded because they were 80 years of age or older and 74 percent because their left ventricular ejection fraction was 0.36 or greater.13 During screening, we identified 1422 eligible patients, of whom 1055 (74 percent) signed a consent form. Of the 1055 patients who were enrolled in the study, 900 were randomly assigned to the implanted-defibrillator group (446 patients) or to the control group (454 patients). The remaining 155 enrolled patients did not undergo randomization; 67 of them were found to meet one or more of the criteria for exclusion between enrollment and the time of randomization; the remaining 88 were not randomly assigned to a group because intraoperative events made the implantation of a defibrillator too risky.13 The base-line characteristics of the two study groups were similar (Table 1Table 1
Base-Line Characteristics of 900 Patients Randomly Assigned to Defibrillator Therapy or to the Control Group.).Adherence to Protocol
During follow-up, there were 70 crossovers: 18 patients in the control group had a defibrillator implanted during the course of the trial; 12 patients assigned to implanted-defibrillator therapy never received a defibrillator because of death or hemodynamic instability in the operating room; and 40 patients in the defibrillator group had their implanted defibrillators removed, primarily because of infection (19 patients), because the implanted defibrillator reached the end of its service period and was not replaced (5), or because the patient requested removal (5). At 42 months, the cumulative rate of crossover to the control group was 10 percent, and the cumulative rate of crossover to the defibrillator group was less than 5 percent.
The use of cardiac drugs was similar in the two groups at the time of discharge after coronary bypass surgery, at three months, and one year after discharge from the hospital (Table 2Table 2
Drug Therapy at Hospital Discharge, at Three Months, and One Year after Coronary-Artery Bypass Surgery.). The rates of use of class I or III antiarrhythmic drugs and beta-blockers were similar in the two groups throughout the trial. Nearly all (93 percent) of 8854 scheduled follow-up visits occurred on schedule.Decision to Report the Primary-End-Point Results
On April 2, 1997, the Data and Safety Monitoring Board took the last of four interim looks at the data on mortality, with 76 percent of the anticipated information on mortality available. The fourth interim analysis showed no difference between the defibrillator and control groups and a negligible chance that a difference would ever be found. Accordingly, the board recommended that data on the primary end point be reported as of April 30, 1997, while the trial continued to pursue its secondary objectives. On April 10, 1997, the director of the National Heart, Lung, and Blood Institute accepted the board's recommendation.
Effect of Implanted-Defibrillator Therapy on Mortality
There were 44 deaths in the first 30 days after randomization: 24 in the defibrillator group and 20 in the control group (P = 0.60). The Kaplan–Meier cumulative-mortality curves for the two treatment groups show no long-term benefit of defibrillator therapy (Figure 1Figure 1
Kaplan–Meier Analysis of the Probability of Death According to Study Group.). During an average (±SD) follow-up of 32±16 months, there were 101 deaths in the defibrillator group (71 from cardiac causes) and 95 in the control group (72 from cardiac causes). The hazard ratio from a Cox regression analysis that compared the risk of death per unit of time in the defibrillator group with that in the control group was 1.07 (95 percent confidence interval, 0.81 to 1.42). A Cox regression model stratified according to clinical center and left ventricular ejection fraction yielded almost identical results (hazard ratio, 1.02; 95 percent confidence interval, 0.76 to 1.35). The hazard ratio (and 95 percent confidence interval) derived from a Cox model after adjustment for the 10 prespecified covariates was similar to the value obtained without adjustment, as was that for the period beginning 30 days after randomization (hazard ratio, 1.03; 95 percent confidence interval, 0.75 to 1.41).Secondary Analyses
Separate Cox regression analyses were performed for each of the 10 prespecified covariates, and no significant interaction with implanted-defibrillator therapy was found — that is, the hazard ratios for the patients assigned to implanted-defibrillator therapy as compared with those in the control group were similar among subgroups defined according to the covariates.
Additional analyses were performed to examine the proportional-hazards assumption of the Cox model according to clinical center and left ventricular ejection fraction. The assumptions in the model remained valid in this stratified analysis.
The cumulative probability of a first implanted-defibrillator discharge in the group assigned to receive defibrillators is shown in Figure 2Figure 2
Kaplan–Meier Analysis of the Probability of the Discharge of a First Shock from the Implanted Cardiac Defibrillator in the Defibrillator Group.. Fifty-seven percent of the patients with an implanted defibrillator received a shock within the first two years after implantation.Adverse Events
Significantly more postoperative infections were reported in the defibrillator group (Table 3Table 3
Postoperative Complications and Adverse Events during Long-Term Follow-up.), and significantly more myocardial infarctions were reported during long-term follow-up in the control group.Discussion
In this trial, we found that survival was not improved by the prophylactic implantation of a defibrillator at the time of elective coronary bypass surgery in patients at high risk for death from ventricular arrhythmia. We enrolled a high proportion of eligible patients sampled from a well-characterized population. The study had a simple design that compared implanted-defibrillator therapy with no preventive antiarrhythmic therapy after coronary bypass surgery. The study groups were well balanced with respect to their base-line clinical characteristics, initial treatment of ischemia, and use of beta-adrenergic–blocking agents and antiarrhythmic drugs during follow-up. There was minimal crossover from one treatment group to the other.
Since ventricular tachyarrhythmias are the most common cause of sudden death,19,20 it was reasonable to postulate that the implanted defibrillator would improve survival among patients at high risk for sudden death. Previous studies have demonstrated that several factors predispose patients to sudden death, including a reduced left ventricular ejection fraction,21-23 heart failure,24-27 and abnormalities on a signal-averaged electrocardiogram.28-30 Patients recruited into the trial constituted a high-risk sample with a 42-month mortality of 24 percent, about four times the mortality among all patients who undergo coronary bypass surgery. However, overall mortality was even higher in the AVID Trial and MADIT. The actuarial 24-month mortality was 32 percent in MADIT,8 24 percent in the AVID Trial,4 and 18 percent in our trial.
It is unlikely that the almost identical mortality rates in the defibrillator and control groups in our trial represent a false negative result. The trial was designed with statistical power of more than 80 percent to detect a 26 percent treatment effect. The probability of observing a hazard-ratio point estimate of 1.0 or greater is about 3 percent if the risk of death was truly 26 percent lower in the defibrillator group than in the control group. At the mortality rates we observed, this trial had statistical power of more than 99 percent to detect an effect as large as that found in MADIT (a 54 percent reduction in the mortality rate).
The central questions raised by this trial, the AVID Trial, and MADIT are why mortality differed among the trials and why the group assigned to implanted-defibrillator therapy did not have lower mortality than the non-defibrillator group in our trial, as it did in the AVID Trial and MADIT. These differences must be due to differences in the patients at enrollment or differences in treatment during follow-up. The patients were similar in terms of age, sex, prevalence of heart failure, and average left ventricular ejection fraction in the three trials. One critical difference was the indicator of arrhythmia used to qualify patients for the study. The AVID Trial (a secondary-prevention trial) required spontaneous sustained ventricular tachyarrhythmias to enroll patients4; MADIT used inducible sustained ventricular tachyarrhythmias that were not suppressed by intravenous procainamide8; and we used abnormalities on a signal-averaged electrocardiogram (MADIT and our trial were primary-prevention trials). Comparison of the results of these trials suggests that the occurrence of sustained ventricular arrhythmias, either natural or induced, is a better marker than abnormalities on the signal-averaged electrocardiogram of a high risk of sudden death that might be prevented by the prophylactic implantation of a defibrillator. The failure of implanted-defibrillator therapy to improve survival in our trial, in contrast to the results in the AVID Trial and MADIT, implies that patients selected for the latter two trials had more episodes of arrhythmia in which death was preventable with implanted-defibrillator therapy.
Interestingly, the cumulative firing rate of the implanted defibrillators in this trial was similar to that in MADIT.8 Since most of the implanted defibrillators in both trials were committed, discharges could occur in response to atrial tachyarrhythmia or unsustained ventricular tachycardia, in addition to ventricular tachyarrhythmia. Because implanted defibrillators with stored electrograms were not marketed until late in the recruitment phase of our trial, only the last 40 defibrillators to be implanted were capable of storing electrograms. Data on the causes of implanted-defibrillator discharges in these 40 patients are being collected.
Differences in the treatment of ischemia may also have contributed to the differences in the response to implanted-defibrillator therapy among these trials. Patients in our trial underwent complete revascularization on the day of randomization. In the AVID Trial and MADIT, fewer patients underwent coronary bypass surgery or angioplasty, and revascularization was, on average, performed longer before recruitment for these trials. Some controlled data on patients with angina,9,10 along with uncontrolled experience in treating survivors of cardiac arrest31-34 or recipients of implanted defibrillators,35 suggest that coronary bypass surgery decreases the risk of sudden death. It is possible that ischemic triggering is important in the genesis of lethal ventricular tachyarrhythmias in coronary heart disease and that revascularization in our trial decreased the incidence of ischemically triggered arrhythmias far below the incidence in the other two trials. Also, it is possible that coronary bypass surgery beneficially altered the autonomic nervous input to the heart. The events committee of the Multicenter Post-Infarction Program estimated that 58 percent of deaths due to arrhythmia were preceded by acute myocardial ischemia,36 and the Cardiac Arrhythmia Pilot Study estimated that proportion at 35 percent.37 That mortality was lower in our trial than in MADIT and the AVID Trial, despite similar age, left ventricular ejection fraction, and rate of heart failure among the patients, is consistent with a significant benefit of cardiac revascularization in terms of survival.
Differences in drug therapy between the randomized groups could contribute in important ways to differences among the trials. Both the AVID Trial and MADIT compared implanted-defibrillator therapy with antiarrhythmic-drug therapy. It is possible that implanted-defibrillator therapy actually had little benefit and that most of the apparent benefit was due to harmful effects of antiarrhythmic drugs. However, almost all patients in the antiarrhythmic-drug group in the AVID Trial and the majority (74 percent) in the conventional-therapy group in MADIT were treated with amiodarone, which other studies suggest has some benefit.38 The rate of use of beta-blockers was substantially higher in the implanted-defibrillator groups in the AVID Trial and MADIT, a fact that may account for some of the reduced mortality in the implanted-defibrillator groups in these studies.39 The rates of use of beta-blockers were not significantly different in the two groups in our trial.
The AVID Trial and MADIT have demonstrated the superiority of implanted-defibrillator therapy over antiarrhythmic-drug therapy in improving survival among patients at risk for sudden death due to ventricular tachyarrhythmias.4,8 The results of our trial tell us that not all patients who are at high risk for death from cardiac causes, as indicated by conventional base-line risk factors, will benefit from an implantable cardioverter–defibrillator.
Future research must be directed at the elucidation of the pathophysiology of sudden death from cardiac causes and at better identification of high-risk patients who will benefit from implantable defibrillators. In addition, the role of coronary bypass surgery in preventing sudden death needs to be clarified. For the present, electrophysiologic studies have a central role in identifying high-risk patients for whom the prophylactic implantation of a defibrillator is indicated.8 Both our results and the literature suggest that patients who present with sustained ventricular arrhythmias should be carefully evaluated and treated for myocardial ischemia.
Supported by grants (HL-48120 and HL-48159) from the National Heart, Lung, and Blood Institute, and by a grant from Guidant/CPI, St. Paul, Minn.
This article was based on data from version 1.0 of the CABG Patch Trial data base.
We are indebted to the patients who participated in this trial and to the attending physicians who referred their patients to this study.
Source Information
Address reprint requests to Dr. Bigger at the Data Coordinating Center, the CABG Patch Trial, PH 103-D, Columbia University, 630 W. 168th St., New York, NY 10032.
The institutions and investigators participating in the trial are listed in the Appendix.
Appendix
The following participated in the trial (asterisks indicate principal investigators): Good Samaritan Hospital, Los Angeles — D. Cannom,* G. Kay,* M. Jones, B. Firth, Y. Park; Sequoia Hospital, Redwood City, Calif. — R. Winkle,* V. Gaudiani,* P. Schmidt, J. Fujii; University of Louisville, Louisville, Ky. — I. Singer,* D. Slater,* A. Cicic, T. Martin; University of Virginia, Charlottesville — J. DiMarco,* I. Kron,* L. Shaw, S. Hennessy, S. Thompson; Presbyterian–University of Pennsylvania Medical Center, Philadelphia — L. Horowitz,* C. Gottlieb,* F. Marchlinski,* H. Kay,* D. Johnson,* R. Keeney, M.A. Roth, M. Deely; Polyclinic Medical Center, Harrisburg, Pa. — D. Scher,* C. Schaffer,* B. Tait; Presbyterian Hospital in the City of New York, New York — H. Spotnitz,* F. Livelli,* L. Pawlicky, N. Chalik, C. De Rosa; Morristown Memorial Hospital, Morristown, N.J. — G. Parr,* S. Winters,* L. Matrisciano; Sentara Norfolk General Hospital, Norfolk, Va. — J. Herre,* L. Baker,* L. Klevan, K. Barackman; University of Florida, Gainesville — A. Curtis,* E. Staples,* C. Nelson, K. Worley; Washington Hospital Center, Washington, D.C. — E. Platia,* L. Mispireta,* S. Boyce,* J. Harrison, P. Bertheaud; Cleveland Clinic Foundation, Cleveland — J. Maloney,* G. Kidwell,* P. McCarthy,* S. Stein; Kaiser Permanente Medical Center, Los Angeles — P. Mahrer,* T. Pfeffer,* N. Dullet, P. Jackimowicz, J. Child; New England Medical Center Hospitals, Boston — M. Estes III,* H. Rastegar,* D. Cliff; Jewish Hospital at Washington University Medical Center, St. Louis — J. Rottman,* R. Kleiger,* T. Wareing,* B. Daily,* C. Hoehn, K. Anderson; Hermann Hospital, University of Texas Medical School, Houston — G. Naccarelli,* A. Dougherty,* M. Sweeney,* D. Wilson, C. Wainwright; Medical College of Virginia, Richmond — M. Wood,* R. Damiano,* L. Arnold, C. Dietrich; Loyola Medical Center, Maywood, Ill. — B. Olshansky,* D. Wilber,* B. Blakeman,* N. Perovic, R. Picchi Szocka, E. Galbraith, A. Florides; East Carolina University School of Medicine, Greenville, N.C. — H. DeAntonio,* J. Williams,* V. Alexander, C. Grill, D. Brewer, M. Mann; St. Joseph's Hospital, Atlanta — H. Kopelman,* K. Thomas,* J. Shaftel, A. Thompson; Westfalische Wilhelms–Universität Münster, Münster, Germany — G. Breithardt,* H. Scheld,* M. Block,* D. Bocker, R. Gradaus; Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany — J. Brachmann,* W. Saggau,* S. Hagl, K. Freigang; LDS Hospital, Salt Lake City — J. Anderson,* R. Millar,* M. Jacobsen, J. Jerman; Florida Hospital, Orlando — K. Schwartz,* C. Stowe,* B. Sickinger, D. Dukes, P. Carlson, N. Granger; Northwest Cardiovascular Research Institute, Spokane, Wash. — H. Goldberg,* W. Coleman,* M. Fisher, K. Brooks, L. Beamer; Nebraska Heart Institute, Lincoln — S. Krueger,* E. Raines,* B. Olander, C. Orosco; Emory University System of Health Care, Atlanta — P. Walter,* E. Jones,* J. Burnette; Minneapolis Heart Institute, Minneapolis — R. Hauser,* K. Arom,* P. Vatterott, C. Johnson, K. Hanson, T. Haas, S. Casey, P. Baldwin; Bowman Gray School of Medicine, Winston-Salem, N.C. — D. Fitzgerald,* J. Hammon, Jr.,* N. Sherrill; University of Nebraska Medical Center, Omaha — J. Windle,* T. Galbraith,* L. Smith, C. Reckling; Brigham and Women's Hospital, Boston — P. Friedman,* G. Couper,* J. Shea, M. Swat; Baystate Medical Center, Springfield, Mass. — R. Engelman,* J. Cook,* C. Gregory; Buffalo General Hospital, Buffalo, N.Y. — S. Raza,* S. Zador,* K. Hoelzl; Hospital of Saint Raphael, New Haven, Conn. — M. Schoenfeld,* M. Marieb,* V. Khachane,* E. Matthews, P. Garofolo; Loma Linda University Medical Center, Loma Linda, Calif. — V. Torres,* S. Gundry,* M. Platt,* V. Bishop; University of Chicago, Chicago — D. Wilber,* R. Karp,* B. Sexton, M. Stasi; Oregon Health Sciences University, Portland — J. Kron,* A. Cobanoglu,* G. Ott,* G. Heywood; Data Coordinating Center, Columbia University — T. Bigger,* J. Fleiss,* S. Bigger, D. Bloomfield, R. Bornholdt, J. Campion, N. DiGiorgio, M. Gallagher, E. Koski, A. Kosok, B. Levin, G. McNeil, P. Meier, L. Morales, P. Namerow, M. Parides, L. Rolnitzky, L. Sosa, R. Steinman; Signal-Averaged Electrocardiographic Reading Center, Philadelphia Heart Institute — C. Gottlieb,* L. Cabrey; Holter Core Laboratory, Columbia University — T. Bigger,* D. Bloomfield, R. Bornholdt, B. Glembocki, P. Gonzalez, R. Steinman; Data and Safety Monitoring Board — D. Echt, C. Furberg (chair), G. Lan, J. Morganroth; End-Point Review Committee — L. Greene, M. Hodges, B. Pitt (chair); National Heart, Lung, and Blood Institute — Debra Egan, Michael Domanski.
- References
References
1
Mirowski M ,Reid PR ,Mower MM , et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-324
Full Text | Web of Science | Medline2
Winkle RA ,Mead RH ,Ruder MA , et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989;13:1353-1361
CrossRef | Web of Science | Medline3
Nisam S ,Kaye SA ,Mower MM ,Hull M . AICD automatic cardioverter defibrillator clinical update: 14 years experience in over 34,000 patients. Pacing Clin Electrophysiol 1995;18:142-147
CrossRef | Web of Science | Medline4
The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
Full Text | Web of Science | Medline5
Eisenberg MS ,Pantridge JF ,Cobb LA ,Geddes LS . The revolution and evolution of prehospital cardiac care. Arch Intern Med 1996;156:1611-1619
CrossRef | Web of Science | Medline6
Lombardi G ,Gallagher J ,Gennis P . Outcome of out-of-hospital cardiac arrest in New York City: the Pre-Hospital Arrest Survival Evaluation (PHASE) Study. JAMA 1994;271:678-683
CrossRef | Web of Science | Medline7
Teo KK ,Yusuf S ,Furberg CD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993;270:1589-1595
CrossRef | Web of Science | Medline8
Moss AJ ,Hall WJ ,Cannom DS , et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940
Full Text | Web of Science | Medline9
Holmes DR Jr ,Davis KB ,Mock MB , et al. The effect of medical and surgical therapy on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986;73:1254-1263
CrossRef | Web of Science | Medline10
Varnauskas E, European Coronary Surgery Study Group
CrossRef11
The CABG Patch Trial Investigators and Coordinators
CrossRef | Web of Science | Medline12
Gottlieb CD ,Bigger JT Jr ,Steinman RC ,Rolnitzky LM . Signal averaged ECG predicts death after CABG surgery. Circulation 1995;92:Suppl I:I-406 abstract.13
Curtis AB, Cannom DS, Bigger JT Jr, et al. Baseline characteristics of patients in the Coronary Artery Bypass Graft (CABG) Patch Trial. Am Heart J (in press).
14
Bigger JT Jr, Parides MK, Meier P, Levin B, Rolnitzky LM. Changes in sample size and length of follow-up to maintain power in the CABG Patch Trial. Control Clin Trials (in press).
15
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science16
Task Force of the Working Group on Arrhythmias of the European Society of Cardiology
Web of Science | Medline17
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science18
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22019
Baum RS ,Alvarez H III ,Cobb LA . Survival after resuscitations from out-of-hospital ventricular fibrillation. Circulation 1974;50:1231-1235
Web of Science | Medline20
Bayes de Luna A ,Coumel PH ,Leclercq JF . Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmias on the basis of data from 157 cases. Am Heart J 1989;117:151-159
CrossRef | Web of Science | Medline21
Bigger JT Jr, Fleiss JL, Kleiger RE, Miller JP, Rolnitzky LM, Multicenter Post-Infarction Research Group
CrossRef | Web of Science | Medline22
Mukharji J ,Rude RE ,Poole WK , et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984;54:31-36
CrossRef | Web of Science | Medline23
Ahnve S ,Gilpin E ,Henning H ,Curtis G ,Collins D ,Ross J Jr . Limitations and advantages of the ejection fraction for defining high risk after acute myocardial infarction. Am J Cardiol 1986;58:872-878[Erratum, J Cardiol 1987;59:A12.]
CrossRef | Web of Science | Medline24
Packer M . Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985;72:681-685
CrossRef | Web of Science | Medline25
Bigger JT Jr . Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987;75:Suppl IV:IV-2826
Cohn JN ,Johnson G ,Ziesche S , et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
Full Text | Web of Science | Medline27
The SOLVD Investigators
Full Text | Web of Science | Medline28
Steinberg JS ,Regan A ,Sciacca RR ,Bigger JT Jr ,Fleiss JL . Predicting arrhythmic events after myocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol 1992;69:13-21
CrossRef | Web of Science | Medline29
el-Sherif N ,Denes P ,Katz R , et al. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period: the Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. J Am Coll Cardiol 1995;25:908-914
CrossRef | Web of Science | Medline30
Signal-averaged electrocardiographyJ Am Coll Cardiol 1996;27:238-249
Web of Science | Medline31
O'Rourke RA. Role of myocardial revascularization in sudden cardiac death. Circulation 1992:85:Suppl I:I-112–I-117.
32
Kelly P ,Ruskin JN ,Vlahakes GJ ,Buckley MJ Jr ,Freeman CS ,Garan H . Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990;15:267-273
CrossRef | Web of Science | Medline33
Kron IL ,Lerman BB ,Haines DE ,Flanagan TL ,DiMarco JP . Coronary artery bypass grafting in patients with ventricular fibrillation. Ann Thorac Surg 1989;48:85-89
CrossRef | Web of Science | Medline34
Every NR ,Fahrenbruch CE ,Hallstrom AP ,Weaver WD ,Cobb LA . Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from out of hospital cardiac arrest. J Am Coll Cardiol 1992;19:1435-1439
CrossRef | Web of Science | Medline35
Levine JH ,Mellits ED ,Baumgardner RA , et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558-566
Web of Science | Medline36
Marcus FI ,Cobb LA ,Edwards JE , et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 1988;61:8-15
CrossRef | Web of Science | Medline37
Greene HL ,Richardson DW ,Barker AH , et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:1-6
CrossRef | Web of Science | Medline38
Amiodarone Trials Meta-Analysis Investigators
CrossRef | Web of Science | Medline39
Pitt B . The role of β-adrenergic blocking agents in preventing sudden cardiac death. Circulation 1992;85:Suppl I:I-107
- Citing Articles (263)
Citing Articles
1
D. G. Katritsis, M. E. Josephson. (2012) Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?. Europace
CrossRef2
Ashok J. Shah, Shinsuke Miyazaki, Amir S. Jadidi, Daniel Scherr, Stephen B. Wilton, Laurent Roten, Patrizio Pascale, Michala Pedersen, Nicolas Derval, Sebastien Knecht, Frederic Sacher, Pierre Jais, Michel Haissaguerre, Meleze Hocini. (2011) Catheter Ablation of Ventricular Fibrillation Storms: Will this Replace Defibrillators?. Cardiac Electrophysiology Clinics 3:4, 689-695
CrossRef3
Krishnakumar Nair, Jack V. Tu, Douglas S. Lee. (2011) Why Are Implantable Cardioverter Defibrillator Outcomes in Practice Different from Clinical Trials?. Cardiac Electrophysiology Clinics 3:4, 511-520
CrossRef4
Stavros E. Mountantonakis, Mathew D. Hutchinson. (2011) Indications for Implantable Cardioverter-Defibrillator Placement in Ischemic Cardiomyopathy and after Myocardial Infarction. Current Heart Failure Reports 8:4, 252-259
CrossRef5
Daniel Jacoby, Oltjan Albajrami, Lavanya Bellumkonda. (2011) Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics 29:4, 485-495
CrossRef6
J. Thijssen, C. J. W. Borleffs, J. B. van Rees, M. K. de Bie, E. T. van der Velde, L. van Erven, J. J. Bax, S. C. Cannegieter, M. J. Schalij. (2011) Driving restrictions after implantable cardioverter defibrillator implantation: an evidence-based approach. European Heart Journal 32:21, 2678-2687
CrossRef7
Ioanna Kosmidou, Keiichi Inada, Jens Seiler, Bruce Koplan, William G. Stevenson, Usha B. Tedrow. (2011) Role of repeat procedures for catheter ablation of postinfarction ventricular tachycardia. Heart Rhythm 8:10, 1516-1522
CrossRef8
T. Jared Bunch, Heidi T. May, Tami L. Bair, Brian G. Crandall, J. Peter Weiss, Jeffrey S. Osborn, Jeffrey L. Anderson, Joseph B. Muhlestein, Benjamin D. Horne, Donald L. Lappe, John D. Day. (2011) Trends in early and late mortality in patients undergoing coronary catheterization for myocardial infarction: implications on observation periods and risk factors to determine ICD candidacy. Heart Rhythm 8:9, 1460-1466
CrossRef9
David J. Whellan, Suzanne Adams, Lisa Bowerman. (2011) Review of Advanced Heart Failure Device Diagnostics Examined in Clinical Trials and the Potential Benefit from Monitoring Capabilities. Progress in Cardiovascular Diseases 54:2, 107-114
CrossRef10
Afschin Gandjour, Astrid Holler Dipl-Ges-Ök, Charles Christian Adarkwah. (2011) Cost-Effectiveness of Implantable Defibrillators after Myocardial Infarction Based on 8-Year Follow-Up Data (MADIT II). Value in Health 14:6, 812-817
CrossRef11
James V. Freeman, Aditya Ullal, Mintu P. Turakhia. (2011) Cost-effectiveness of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics 3:3, 421-440
CrossRef12
(2011) CABG in Patients with Left Ventricular Dysfunction. New England Journal of Medicine 365:5, 468-471
Full Text13
Daniel Scharfstein, Georgiana Onicescu, Steven Goodman, Rachel Whitaker. (2011) Analysis of subgroup effects in randomized trials when subgroup membership is missing: application to the second Multicenter Automatic Defibrillator Intervention Trial. Journal of the Royal Statistical Society: Series C (Applied Statistics) 60:4, 607-617
CrossRef14
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef15
Johannes B. van Rees, Mihály K. de Bie, Joep Thijssen, C. Jan Willem Borleffs, Martin J. Schalij, Lieselot van Erven. (2011) Implantation-Related Complications of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices. Journal of the American College of Cardiology 58:10, 995-1000
CrossRef16
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef17
Eric C. Stecker, Sumeet S. Chugh. (2011) Prediction of sudden cardiac death: next steps in pursuit of effective methodology. Journal of Interventional Cardiac Electrophysiology 31:2, 101-107
CrossRef18
Esther S.H. Kim, Thomas P. Carrigan, Venu Menon. (2011) International Participation in Cardiovascular Randomized Controlled Trials Sponsored by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology 58:7, 671-676
CrossRef19
Johannes Holzmeister, Christophe Leclercq. (2011) Implantable cardioverter defibrillators and cardiac resynchronisation therapy. The Lancet 378:9792, 722-730
CrossRef20
John R. Wilson. (2011) Rhetorical Strategies Used in the Reporting of Implantable Defibrillator Primary Prevention Trials. The American Journal of Cardiology 107:12, 1806-1811
CrossRef21
F. Leyva, I. Fernandez Lozano, J. Morgan. (2011) Cardioverter-defibrillators: a cost or an investment?. Europace 13:Supplement 2, ii25-ii31
CrossRef22
Samir Saba. (2011) Sudden Cardiac Death Risk Stratification and Assessment: Primary Prevention Based on Ejection Fraction Criteria. Heart Failure Clinics 7:2, 175-183
CrossRef23
G. H. van Welsenes, J. B. van Rees, C. J. W. Borleffs, S. C. Cannegieter, J. J. Bax, L. van Erven, M. J. Schalij. (2011) Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace 13:3, 389-394
CrossRef24
M. F. Nageh, J. J. Kim, J. Chung, J. F. Yao. (2011) The role of implantable cardioverter defibrillators in high-risk CABG patients identified early post-cardiac surgery. Europace 13:1, 70-76
CrossRef25
F. Braunschweig, G. Boriani, A. Bauer, R. Hatala, C. Herrmann-Lingen, J. Kautzner, S. S. Pedersen, S. Pehrson, R. Ricci, M. J. Schalij. (2010) Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management. Europace 12:12, 1673-1690
CrossRef26
D. A. M. J. Theuns, T. Smith, M. G. M. Hunink, G. H. Bardy, L. Jordaens. (2010) Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 12:11, 1564-1570
CrossRef27
Wilbert S Aronow. (2010) Use of implantable cardioverter-defibrillators. Future Cardiology 6:6, 859-870
CrossRef28
Wilbert S Aronow. (2010) Implantable Cardioverter-Defibrillators. American Journal of Therapeutics 17:6, e208-e220
CrossRef29
Ralph Lazzara. (2010) Spatial vectorcardiogram to predict risk for sudden arrhythmic death: Phoenix risen from the ashes. Heart Rhythm 7:11, 1614-1615
CrossRef30
Alon Barsheshet, Ilan Goldenberg, Craig R. Narins, Arthur J. Moss, Scott McNitt, Paul J. Wang, David T. Huang, W. Jackson Hall, Wojciech Zareba, Michael Eldar, Victor Guetta. (2010) Time dependence of life-threatening ventricular tachyarrhythmias after coronary revascularization in MADIT-CRT. Heart Rhythm 7:10, 1421-1427
CrossRef31
Anoop K Shetty, Miles WH Behan, Julian Bostock, C Aldo Rinaldi. (2010) Device therapy for the management of cardiac tachyarrhythmias. Expert Review of Cardiovascular Therapy 8:9, 1257-1266
CrossRef32
Niloufar Tabatabaei, Stephen C. Hammill. (2010) Role of the Automatic Implantable Cardioverter Defibrillator in the Post-myocardial Infarction Patient. Current Cardiovascular Risk Reports 4:5, 321-326
CrossRef33
Brian Feingold, Gaurav Arora, Steven A. Webber, Kenneth J. Smith. (2010) Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Children With Dilated Cardiomyopathy. Journal of Cardiac Failure 16:9, 734-741
CrossRef34
Gillian D. Sanders, Melissa H. Kong, Sana M. Al-Khatib, Eric D. Peterson. (2010) Cost-effectiveness of implantable cardioverter defibrillators in patients ≥65 years of age. American Heart Journal 160:1, 122-131
CrossRef35
Badri Chandrasekaran, Peter J Cowburn. (2010) Heart failure: the challenge of selecting patients for implantable cardioverter defibrillator therapy. Expert Review of Medical Devices 7:4, 461-467
CrossRef36
Gary S. Francis, Barry H. Greenberg, Daphne T. Hsu, Brian E. Jaski, Mariell Jessup, Martin M. LeWinter, Francis D. Pagani, Ileana L. Piña, Marc J. Semigran, Mary Norine Walsh, David H. Wiener, Clyde W. Yancy. (2010) ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant. Journal of the American College of Cardiology 56:5, 424-453
CrossRef37
Jonathan P. Piccini, Aijing Z. Starr, John R. Horton, Linda K. Shaw, Kerry L. Lee, Sana M. Al-Khatib, Ami E. Iskandrian, Christopher M. O'Connor, Salvador Borges-Neto. (2010) Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging and the Risk of Sudden Cardiac Death in Patients With Coronary Disease and Left Ventricular Ejection Fraction >35%. Journal of the American College of Cardiology 56:3, 206-214
CrossRef38
Guy Amit, David S. Rosenbaum, Dennis M. Super, Otto Costantini. (2010) Microvolt T-wave alternans and electrophysiologic testing predict distinct arrhythmia substrates: Implications for identifying patients at risk for sudden cardiac death. Heart Rhythm 7:6, 763-768
CrossRef39
JERRY M. JOHN, AHMED HUSSEIN, NASER IMRAN, SAMUEL J. DURHAM, BLAIR P. GRUBB, YOUSUF KANJWAL. (2010) Underutilization of Implantable Cardioverter Defibrillators Post Coronary Artery Bypass Grafting in Patients with Systolic Dysfunction. Pacing and Clinical Electrophysiology 33:6, 727-733
CrossRef40
Heart Failure Society of America. (2010) Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 16:6, 475-539
CrossRef41
(2010) Section 9: Electrophysiology Testing and the Use of Devices in Heart Failure. Journal of Cardiac Failure 16:6, e115-e121
CrossRef42
Scott M. Berry, K. Jack Ishak, Bryan R. Luce, Donald A. Berry. (2010) Bayesian Meta-Analyses for Comparative Effectiveness and Informing Coverage Decisions. Medical Care 48, S137-S144
CrossRef43
Keiichi Inada, Kurt C. Roberts-Thomson, Jens Seiler, Daniel Steven, Usha B. Tedrow, Bruce A. Koplan, William G. Stevenson. (2010) Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease. Heart Rhythm 7:6, 740-744
CrossRef44
Richard N Vest, Michael R Gold. (2010) Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Current Opinion in Cardiology 25:3, 268-275
CrossRef45
Darren Green, Paul R. Roberts. (2010) VENTRICULAR ARRHYTHMIAS AND SUDDEN DEATH IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Renal Care 36, 54-60
CrossRef46
Rodrigo Antonini Ribeiro, Steffan Frosi Stella, Suzi Alves Camey, Leandro Ioschpe Zimerman, Maurício Pimentel, Luis Eduardo Rohde, Carísi Anne Polanczyk. (2010) Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brazil: Primary Prevention Analysis in the Public Sector. Value in Health 13:2, 160-168
CrossRef47
Miia K. Hyytinen-Oinas, Kari Ylitalo, Mari Karsikas, Tapio Seppänen, M. J. Pekka Raatikainen, Paavo Uusimaa, Heikki V. Huikuri, Juha S. Perkiömäki. (2010) Electrocardiographic abnormalities and ventricular tachyarrhythmias after myocardial infarction. Scandinavian Cardiovascular Journal 44:1, 15-23
CrossRef48
Myron C. Gerson, Mouhamad Abdallah, James N. Muth, Alexandru I. Costea. (2010) Will Imaging Assist in the Selection of Patients With Heart Failure for an ICD?. JACC: Cardiovascular Imaging 3:1, 101-110
CrossRef49
Elizabeth A. Stephenson, Andrew M. Davis. 2010. Electrophysiology, Pacing, and Devices. , 379-413.
CrossRef50
Stavros Mountantonakis, Mathew D. Hutchinson. (2009) Who should receive an implantable cardioverter-defibrillator after myocardial infarction?. Current Heart Failure Reports 6:4, 236-244
CrossRef51
S. Brenner, S. Störk, C.E. Angermann. (2009) Behandlung der chronischen Linksherzinsuffizienz. Der Internist 50:12, 1325-1336
CrossRef52
Ilknur Can, Venkatakrishna N. Tholakanahalli. (2009) Current status of implantable cardioverter-defibrillator therapy in heart failure. Current Heart Failure Reports 6:3, 199-209
CrossRef53
Andrew E. Epstein. (2009) Update on primary prevention implantable cardioverter-defibrillator therapy. Current Cardiology Reports 11:5, 335-342
CrossRef54
, J. Vijgen, G. Botto, J. Camm, C.-J. Hoijer, W. Jung, J.-Y. Le Heuzey, A. Lubinski, T. M. Norekval, M. Santomauro, M. Schalij, J.-P. Schmid, P. Vardas. (2009) Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 11:8, 1097-1107
CrossRef55
Robert J. Myerburg, Vivek Reddy, Agustin Castellanos. (2009) Indications for Implantable Cardioverter-Defibrillators Based on Evidence and Judgment. Journal of the American College of Cardiology 54:9, 747-763
CrossRef56
Komandoor Srivathsan, Daniel WC Ng, Farouk Mookadam. (2009) Ventricular tachycardia and ventricular fibrillation. Expert Review of Cardiovascular Therapy 7:7, 801-809
CrossRef57
Carlo Briguori, Tiziana Claudia Aranzulla, Flavio Airoldi, John Cosgrave, Davide Tavano, Iassen Michev, Matteo Montorfano, Mauro Carlino, Alfredo Castelli, Massimo Giuseppe Sangiorgi, Antonio Colombo. (2009) Stent implantation in patients with severe left ventricular systolic dysfunction. International Journal of Cardiology 135:3, 376-384
CrossRef58
Derek V. Exner. (2009) Noninvasive risk stratification after myocardial infarction: Rationale, current evidence and the need for definitive trials. Canadian Journal of Cardiology 25, 21A-27A
CrossRef59
Wilbert S. Aronow. (2009) Treatment of Ventricular Arrhythmias in the Elderly. Cardiology in Review 17:3, 136-146
CrossRef60
Kristian B. Filion, Xuanqian Xie, Charlotte J. van der Avoort, Nandini Dendukuri, James M. Brophy. (2009) Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness study. International Journal of Technology Assessment in Health Care 25:02, 151
CrossRef61
Jeffrey J. Goldberger. (2009) Evidence-based analysis of risk factors for sudden cardiac death. Heart Rhythm 6:3, S2-S7
CrossRef62
Christina M. Holmgren, Britta M. Nyström, Thomas K. Karlsson, Johan D. Herlitz, Nils G. Edvardsson. (2009) Presumed arrhythmic death in consecutive survivors of acute myocardial infarction – implications for primary implantable cardioverter defibrillator implantation. Coronary Artery Disease 20:2, 155-162
CrossRef63
Guy Amit, Otto Costantini, David S. Rosenbaum. (2009) Can we alternate between T-wave alternans testing methods?. Heart Rhythm 6:3, 338-340
CrossRef64
Mithilesh Das. (2009) Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death. Expert Review of Cardiovascular Therapy 7:2, 181-195
CrossRef65
Jaydutt B. Patel, Bruce A. Koplan. (2009) ICD implantation in patients with ischemic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 11:1, 3-9
CrossRef66
Vikas Kuriachan, Derek V. Exner. (2009) Role of risk stratification after myocardial infarction. Current Treatment Options in Cardiovascular Medicine 11:1, 10-21
CrossRef67
Derek V Exner. (2009) Implantable cardioverter defibrillator therapy for patients with less severe left ventricular dysfunction. Current Opinion in Cardiology 24:1, 61-67
CrossRef68
Yoshio Uetsuka. (2009) Iryo To Shakai 19:1, 97-106
CrossRef69
Marzia Leacche, Jorge M. Balaguer, John G. Byrne. (2008) Role of cardiac surgery in the post-myocardial infarction patient with heart failure. Current Heart Failure Reports 5:4, 204-210
CrossRef70
Alfred P. Hallstrom, D. George Wyse, John McAnulty, . (2008) Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis. Journal of Interventional Cardiac Electrophysiology 23:3, 159-166
CrossRef71
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef72
Myerburg, Robert J., . (2008) Implantable Cardioverter–Defibrillators after Myocardial Infarction. New England Journal of Medicine 359:21, 2245-2253
Full Text73
John P. Boehmer, Mark D. Carlson, Teresa Marco, Brian E. Jaski, Steven L. Higgins, Charles Kennergren, Andrew E. Epstein. (2008) Adjudication of mortality events in a heart failure–arrhythmia trial by a multiparameter descriptive method: Comparison with methods used in heart failure trials and methods used in arrhythmia trials. Journal of Interventional Cardiac Electrophysiology 23:2, 101-110
CrossRef74
Philippe Menasché. (2008) Skeletal myoblasts and cardiac repair. Journal of Molecular and Cellular Cardiology 45:4, 545-553
CrossRef75
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef76
Ian N. Sabir, Juliet A. Usher-Smith, Christopher L.-H. Huang, Andrew A. Grace. (2008) Risk stratification for sudden cardiac death. Progress in Biophysics and Molecular Biology 98:2-3, 340-346
CrossRef77
Jeffrey J. Goldberger, Michael E. Cain, Stefan H. Hohnloser, Alan H. Kadish, Bradley P. Knight, Michael S. Lauer, Barry J. Maron, Richard L. Page, Rod S. Passman, David Siscovick, William G. Stevenson, Douglas P. Zipes. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm 5:10, e1-e21
CrossRef78
SANA M AL-KHATIB, ANNE S. HELLKAMP, KERRY L LEE, JILL ANDERSON, JEANNE E. POOLE, DANIEL B. MARK, GUST H. BARDY, . (2008) Implantable Cardioverter Defibrillator Therapy in Patients with Prior Coronary Revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Journal of Cardiovascular Electrophysiology 19:10, 1059-1065
CrossRef79
Mark, Daniel B., Anstrom, Kevin J., Sun, Jie L., Clapp-Channing, Nancy E., Tsiatis, Anastasios A., Davidson-Ray, Linda, Lee, Kerry L., Bardy, Gust H., . (2008) Quality of Life with Defibrillator Therapy or Amiodarone in Heart Failure. New England Journal of Medicine 359:10, 999-1008
Full Text80
Jeffrey J. Goldberger, Michael E. Cain, Stefan H. Hohnloser, Alan H. Kadish, Bradley P. Knight, Michael S. Lauer, Barry J. Maron, Richard L. Page, Rod S. Passman, David Siscovick, William G. Stevenson, Douglas P. Zipes. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Journal of the American College of Cardiology 52:14, 1179-1199
CrossRef81
Roderick Tung, Peter Zimetbaum, Mark E. Josephson. (2008) A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology 52:14, 1111-1121
CrossRef82
Kenneth M. Stein. (2008) Noninvasive Risk Stratification for Sudden Death: Signal-Averaged Electrocardiography, Nonsustained Ventricular Tachycardia, Heart Rate Variability, Baroreflex Sensitivity, and QRS Duration. Progress in Cardiovascular Diseases 51:2, 106-117
CrossRef83
Andrew E. Epstein. (2008) Benefits of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology 52:14, 1122-1127
CrossRef84
L. Ding, W. Hua, H. Niu, K. Chen, S. Zhang. (2008) Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. Europace 10:9, 1034-1041
CrossRef85
Pasquale Santangeli, Fabio Infusino, Gregory Angelo Sgueglia, Alfonso Sestito, Gaetano Antonio Lanza. (2008) Ventricular late potentials: a critical overview and current applications. Journal of Electrocardiology 41:4, 318-324
CrossRef86
Ronni Levy, Andrea DellaValle, A. Serdar Atav, Afazal ur Rehman, Allan H. Sklar, Nicolas J. Stamato. (2008) The Relationship Between Glomerular Filtration Rate and Survival in Patients Treated with an Implantable Cardioverter Defibrillator. Clinical Cardiology 31:6, 265-269
CrossRef87
Andrew E. Epstein, John P. DiMarco, Kenneth A. Ellenbogen, N. A. Mark Estes, Roger A. Freedman, Leonard S. Gettes, A. Marc Gillinov, Gabriel Gregoratos, Stephen C. Hammill, David L. Hayes, Mark A. Hlatky, L. Kristin Newby, Richard L. Page, Mark H. Schoenfeld, Michael J. Silka, Lynne Warner Stevenson, Michael O. Sweeney, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, David P. Faxon, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Lynn G. Tarkington, Clyde W. Yancy. (2008) ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Heart Rhythm 5:6, e1-e62
CrossRef88
Andrew E. Epstein, John P. DiMarco, Kenneth A. Ellenbogen, N.A. Mark Estes, Roger A. Freedman, Leonard S. Gettes, A. Marc Gillinov, Gabriel Gregoratos, Stephen C. Hammill, David L. Hayes, Mark A. Hlatky, L. Kristin Newby, Richard L. Page, Mark H. Schoenfeld, Michael J. Silka, Lynne Warner Stevenson, Michael O. Sweeney. (2008) ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology 51:21, e1-e62
CrossRef89
Ilan Goldenberg, Arthur J. Moss. (2008) Implantable Device Therapy. Progress in Cardiovascular Diseases 50:6, 449-474
CrossRef90
C. A. Herzog, J. W. Strief, A. J. Collins, D. T. Gilbertson. (2008) Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?. Nephrology Dialysis Transplantation 23:8, 2629-2633
CrossRef91
Michael T. Koller, Theo Stijnen, Ewout W. Steyerberg, Jacobus Lubsen. (2008) Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios. Journal of Clinical Epidemiology 61:4, 365-372
CrossRef92
Wolfram Grimm. (2008) Outcomes of elderly heart failure recipients of ICD and CRT. International Journal of Cardiology 125:2, 154-160
CrossRef93
Abeel A. Mangi. (2008) Invited Commentary. The Annals of Thoracic Surgery 85:4, 1281-1282
CrossRef94
Wilbert S. Aronow, Carmine Sorbera. 2008. Ventricular Arrhythmias in the Elderly. , 605-626.
CrossRef95
ANDREAS W. SCHOENENBERGER, PAUL ERNE, STEPHAN AMMANN, GERHARD GILLMANN, RICHARD KOBZA, ANDREAS E. STUCK. (2008) Prediction of Arrhythmic Events after Myocardial Infarction Based on Signal-Averaged Electrocardiogram and Ejection Fraction. Pacing and Clinical Electrophysiology 31:2, 221-228
CrossRef96
Christopher H George, Steven R Barberini-Jammaers, Carsten T Muller. (2008) Refocussing therapeutic strategies for cardiac arrhythmias: defining viable molecular targets to restore cardiac ion flux. Expert Opinion on Therapeutic Patents 18:1, 1-19
CrossRef97
Ilan Goldenberg, Anant K. Vyas, W. Jackson Hall, Arthur J. Moss, Hongyue Wang, Hua He, Wojciech Zareba, Scott McNitt, Mark L. Andrews. (2008) Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. Journal of the American College of Cardiology 51:3, 288-296
CrossRef98
Ulrik Sartipy, Anders Albåge, Per Insulander, Dan Lindblom. (2007) Surgery for ventricular tachycardia in patients undergoing surgical ventricular restoration: The Karolinska approach. Journal of Interventional Cardiac Electrophysiology 19:3, 171-178
CrossRef99
Ilan Goldenberg, Arthur J. Moss. (2007) Treatment of Arrhythmias and Use of Implantable Cardioverter-Defibrillators to Improve Survival in Elderly Patients with Cardiac Disease. Heart Failure Clinics 3:4, 519-528
CrossRef100
Guy Amit, Otto Costantini. (2007) SCD in patients with cardiomyopathy: Use of microvolt T-wave alternans and other noninvasive tests for risk stratification and prevention of SCD. Current Treatment Options in Cardiovascular Medicine 9:5, 345-355
CrossRef101
Mithilesh K. Das, Rajdeep Gaitonde, John M. Miller. (2007) Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death. Current Cardiology Reports 9:5, 371-380
CrossRef102
Mintu Turakhia, Zian H. Tseng. (2007) Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapy. Current Problems in Cardiology 32:9, 501-546
CrossRef103
Gaetano Antonio Lanza. (2007) The Electrocardiogram as a Prognostic Tool for Predicting Major Cardiac Events. Progress in Cardiovascular Diseases 50:2, 87-111
CrossRef104
M. Roser, S. Götze. (2007) ICD-Therapie. Der Kardiologe 1:2, 149-164
CrossRef105
Philippe Menasché. (2007) Skeletal Myoblasts as a Therapeutic Agent. Progress in Cardiovascular Diseases 50:1, 7-17
CrossRef106
David R. Holmes, Lauren J. Kim, Maria Mori Brooks, Kevin E. Kip, Hartzell V. Schaff, Katherine M. Detre, Robert L. Frye. (2007) The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. The Journal of Thoracic and Cardiovascular Surgery 134:1, 38-46.e1
CrossRef107
Sana M. Al-Khatib, Gillian D. Sanders, J. Thomas Bigger, Alfred E. Buxton, Robert M. Califf, Mark Carlson, Anne Curtis, Jeptha Curtis, Eric Fain, Bernard J. Gersh, Michael R. Gold, Ali Haghighi-Mood, Stephen C. Hammill, Jeff Healey, Mark Hlatky, Stefan Hohnloser, Raymond J. Kim, Kerry Lee, Daniel Mark, Marcus Mianulli, Brent Mitchell, Eric N. Prystowsky, Joseph Smith, David Steinhaus, Wojciech Zareba. (2007) Preventing tomorrow's sudden cardiac death today. American Heart Journal 153:6, 941-950
CrossRef108
Gillian D. Sanders, Sana M. Al-Khatib, Elise Berliner, J. Thomas Bigger, Alfred E. Buxton, Robert M. Califf, Mark Carlson, Anne B. Curtis, Jeptha P. Curtis, Michael Domanski, Eric Fain, Bernard J. Gersh, Michael R. Gold, Jeffrey Goldberger, Ali Haghighi-Mood, Stephen C. Hammill, Joel Harder, Jeffrey Healey, Mark A. Hlatky, Stefan H. Hohnloser, Kerry L. Lee, Daniel B. Mark, Brent Mitchell, Steve Phurrough, Eric Prystowsky, Joseph M. Smith, Norman Stockbridge, Robert Temple. (2007) Preventing tomorrow's sudden cardiac death today. American Heart Journal 153:6, 951-959
CrossRef109
Katia Noyes, Ethan Corona, Jack Zwanziger, W Jackson Hall, Hongwei Zhao, Hongkun Wang, Arthur J. Moss, Andrew W. Dick. (2007) Health-Related Quality of Life Consequences of Implantable Cardioverter Defibrillators. Medical Care 45:5, 377-385
CrossRef110
Sorin V. Pusca, John D. Puskas. (2007) Revascularization in Heart Failure: Coronary Bypass or Percutaneous Coronary Intervention?. Heart Failure Clinics 3:2, 211-228
CrossRef111
George M. Comas, Barry C. Esrig, Mehmet C. Oz. (2007) Surgery for Myocardial Salvage in Acute Myocardial Infarction and Acute Coronary Syndromes. Heart Failure Clinics 3:2, 181-210
CrossRef112
Andrew E. Epstein, Christina A. Baessler, Anne B. Curtis, N.A. Mark Estes, Bernard J. Gersh, Blair Grubb, L. Brent Mitchell. (2007) Addendum to “Personal and Public Safety Issues Related to Arrhythmias that May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement from the American Heart Association and the North American Society of Pacing and Electrophysiology”. Heart Rhythm 4:3, 386-393
CrossRef113
Ilan Goldenberg, Arthur J. Moss. (2007) Treatment of Arrhythmias and Use of Implantable Cardioverter-Defibrillators to Improve Survival in Elderly Patients with Cardiac Disease. Clinics in Geriatric Medicine 23:1, 205-219
CrossRef114
Rishi Sukhija, Vimal Mehta, Marino Leonardi, Jawahar L. Mehta. (2007) Implantable cardioverter defibrillators for prevention of sudden cardiac Death. Clinical Cardiology 30:1, 3-8
CrossRef115
Jackie Bryant, Hakan Brodin, Emma Loveman, Andrew Clegg. (2007) Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation. International Journal of Technology Assessment in Health Care 23:01,
CrossRef116
Patrizio Pascale, Martin Fromer. (2007) Time Dependence of Defibrillator Benefit Postcoronary Revascularization. Journal of the American College of Cardiology 49:1, 124-125
CrossRef117
Ilan Goldenberg, Arthur J. Moss. (2007) Reply. Journal of the American College of Cardiology 49:1, 125
CrossRef118
GIOVANNI LUCA BOTTO, MARIO LUZI, FRANCO RUFFA, GIOVANNI RUSSO, GIOVANNI FERRARI. (2006) Atrial Tachyarrhythmias in Primary and Secondary Prevention ICD Recipients: Clinical and Prognostic Data. Pacing and Clinical Electrophysiology 29:s2, S48-S53
CrossRef119
Adnan Siddiqui, Peter R Kowey. (2006) Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Current Opinion in Internal Medicine 5:6, 544-552
CrossRef120
(2006) Guías de Práctica Clínica del ACC/AHA/ESC 2006 sobre el manejo de pacientes con arritmias ventriculares y la prevención de la muerte cardiaca súbita.Versión resumida. Revista Española de Cardiología 59:12, 1328.e1-1328.e51
CrossRef121
N. N. HENYAN, C. M. WHITE, E. L. GILLESPIE, K. SMITH, C. I. COLEMAN, J. KLUGER. (2006) The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. Journal of Internal Medicine 260:5, 467-473
CrossRef122
Sandeep Nathan, William Piccione, Arun Kumar, Steve Attanasio, Gary L. Schaer. (2006) Erosion of an Extrapericardial Implantable Cardioverter Defibrillator Patch Through the Gastric Fundus With Fistulous Tract Formation. Cardiology in Review 14:6, e21-e23
CrossRef123
Jeanne E. Poole. (2006) New indications for implantable defibrillator therapy. Current Cardiology Reports 8:5, 330-335
CrossRef124
Douglas P. Zipes, A. John Camm, Martin Borggrefe, Alfred E. Buxton, Bernard Chaitman, Martin Fromer, Gabriel Gregoratos, George Klein, Arthur J. Moss, Robert J. Myerburg, Silvia G. Priori, Miguel A. Quinones, Dan M. Roden, Michael J. Silka, Cynthia Tracy, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Elliott M. Antman, Jeffrey L. Anderson, Sharon A. Hunt, Jonathan L. Halperin, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Silvia G. Priori, Jean-Jacques Blanc, Andrzej Budaj, A. John Camm, Veronica Dean, Jaap W. Deckers, Catherine Despres, Kenneth Dickstein, John Lekakis, Keith McGregor, Marco Metra, Joao Morais, Ady Osterspey, Juan Luis Tamargo, José Luis Zamorano. (2006) ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology 48:5, e247-e346
CrossRef125
Douglas P. Zipes, A. John Camm, Martin Borggrefe, Alfred E. Buxton, Bernard Chaitman, Martin Fromer, Gabriel Gregoratos, George Klein, Arthur J. Moss, Robert J. Myerburg, Silvia G. Priori, Miguel A. Quinones, Dan M. Roden, Michael J. Silka, Cynthia Tracy, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Elliott M. Antman, Jeffrey L. Anderson, Sharon A. Hunt, Jonathan L. Halperin, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Silvia G. Priori, Jean-Jacques Blanc, Andrzej Budaj, A. John Camm, Veronica Dean, Jaap W. Deckers, Catherine Despres, Kenneth Dickstein, John Lekakis, Keith McGregor, Marco Metra, Joao Morais, Ady Osterspey, Juan Luis Tamargo, José Luis Zamorano. (2006) ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary. Journal of the American College of Cardiology 48:5, 1064-1108
CrossRef126
Craig H. Selzman, Rajendra S. Bhati, Brett C. Sheridan, William E. Stansfield, Michael R. Mill. (2006) Surgical Therapy for Heart Failure. Journal of the American College of Surgeons 203:2, 226-239
CrossRef127
Leslie A. Saxon. (2006) Patient Selection for Primary Prevention ICDs—Are EPs Shocking Patients Into Consent?. Journal of Cardiac Failure 12:6, 413-415
CrossRef128
Oscar Bernal, Concepción Moro. (2006) Arritmias cardiacas en la mujer. Revista Española de Cardiología 59:6, 609-618
CrossRef129
Sheharyar Ali, Eduardo S. Antezano. (2006) Sudden Cardiac Death. Southern Medical Journal 99:5, 502-510
CrossRef130
Sami Viskin. (2006) Prediction versus prevention of sudden cardiac death. The Lancet 367:9523, 1639-1641
CrossRef131
Mina K. Chung, James O. O’Neill. (2006) Reply to the Editor. The Journal of Thoracic and Cardiovascular Surgery 131:5, 1211
CrossRef132
Anne M. Gillis. (2006) Tincture of Time. Journal of the American College of Cardiology 47:9, 1818-1819
CrossRef133
Ilan Goldenberg, Arthur J. Moss, Scott McNitt, Wojciech Zareba, W. Jackson Hall, Mark L. Andrews, David J. Wilber, Helmut U. Klein. (2006) Time Dependence of Defibrillator Benefit After Coronary Revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. Journal of the American College of Cardiology 47:9, 1811-1817
CrossRef134
David A. Cesario, G. William Dec. (2006) Implantable Cardioverter- Defibrillator Therapy in Clinical Practice. Journal of the American College of Cardiology 47:8, 1507-1517
CrossRef135
PETRI KORHONEN, TERHI HUSA, ILKKA TIERALA, HEIKKI VAANANEN, MARKKU MAKIJARVI, TOIVO KATILA, LAURI TOIVONEN. (2006) Increased Intra-QRS Fragmentation in Magnetocardiography as a Predictor of Arrhythmic Events and Mortality in Patients with Cardiac Dysfunction After Myocardial Infarction. Journal of Cardiovascular Electrophysiology 17:4, 396-401
CrossRef136
JONATHAN S. STEINBERG, HOWARD LEVITT. (2006) Magnetocardiography Throws Its Hat in the Ring. Journal of Cardiovascular Electrophysiology 17:4, 402-404
CrossRef137
Gabor Duray, Carsten W Israel, Stefan H Hohnloser. (2006) Recent primary prevention implantable cardioverter defibrillator trials. Current Opinion in Internal Medicine 5:2, 154-158
CrossRef138
Akshay S. Desai, Bruce A Koplan. 2006. Device Therapy for Advanced Heart Disease: The Role of Implantable Defibrillators. , 301-324.
CrossRef139
James P. Daubert, Henry W. Sesselberg, David T. Huang. (2006) Implantable Cardioverter-Defibrillators for Primary Prevention: How Do the Data Pertain to the Aged?. The American Journal of Geriatric Cardiology 15:2, 88-92
CrossRef140
Philippe Menasché, Michel Desnos, Albert A Hagège. (2006) Routine delivery of myoblasts during coronary artery bypass surgery: why not?. Nature Clinical Practice Cardiovascular Medicine 3, S90-S93
CrossRef141
Robert D Winslow, Sean Pinney, Valentin Fuster. (2006) Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure. Nature Clinical Practice Cardiovascular Medicine 3:2, 86-93
CrossRef142
Heart Failure Society of America. (2006) Section 9: Electrophysiologic Testing and the Use of Devices in Heart Failure. Journal of Cardiac Failure 12:1, e70-e75
CrossRef143
José Azpitarte. (2006) Profilaxis primaria con desfibrilador-cardioversor implantable en la insuficiencia cardiaca: un punto de vista clínico. Revista Española de Cardiología 59, 10-22
CrossRef144
Stephen Minor, Toshio Akiyama. (2006) Ventricular Arrhythmias in the Elderly. Journal of Arrhythmia 22:1, 19-30
CrossRef145
Ivan C.K. Ho, Jonathan J. Passeri, Mary L. Guy, Jeremy N. Ruskin, Patrick T. Ellinor. (2006) Impact of the Multicenter Automatic Defibrillator Implantation Trial on Clinical Practice. Annals of Noninvasive Electrocardiology 11:1, 20-27
CrossRef146
Andrew E. Epstein. (2005) New insights into cardiac resynchronization therapy. Clinical Cardiology 28:S1, 45-50
CrossRef147
John D. Fisher. (2005) Who Needs a Defibrillator?. Journal of the American College of Cardiology 46:9, 1727-1728
CrossRef148
James A. Reiffel. (2005) Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clinical Cardiology 28:S1, 28-37
CrossRef149
Sanders, Gillian D., Hlatky, Mark A., Owens, Douglas K., . (2005) Cost-Effectiveness of Implantable Cardioverter–Defibrillators. New England Journal of Medicine 353:14, 1471-1480
Full Text150
Prash Jayaraj, Kevin M. Monahan. (2005) Sudden cardiac death and the role of device therapy in dilated cardiomyopathy. Current Heart Failure Reports 2:3, 124-127
CrossRef151
Jesús Herreros. (2005) Cirugía coronaria. Evolución en la última década. Indicaciones y resultados actuales. Revista Española de Cardiología 58:9, 1107-1116
CrossRef152
Robert D Winslow, Davendra Mehta, Valentin Fuster. (2005) Sudden cardiac death: mechanisms, therapies and challenges. Nature Clinical Practice Cardiovascular Medicine 2:7, 352-360
CrossRef153
T. Jared Bunch, Stephen C. Hammill, Roger D. White. (2005) Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival. Mayo Clinic Proceedings 80:6, 774-782
CrossRef154
Eric M. Crespo, Jane Kim, Kimberly A. Selzman. (2005) The Use of Implantable Cardioverter Defibrillators for the Prevention of Sudden Cardiac Death: A Review of the Evidence and Implications. The American Journal of the Medical Sciences 329:5, 238-246
CrossRef155
Aslan T. Turer, Sunil V. Rao. (2005) Device Therapy in the Management of Congestive Heart Failure. Cardiology in Review 13:3, 130-138
CrossRef156
Mahi Lakshmi Ashwath, Felix O. Sogade. (2005) Ejection Fraction and QRS Width as Predictors of Event Rates in Patients with Implantable Cardioverter Defibrillators. Southern Medical Journal 98:5, 513-517
CrossRef157
Paul S. Chan, Rodney A. Hayward. (2005) Mortality Reduction by Implantable Cardioverter-Defibrillators in High-Risk Patients With Heart Failure, Ischemic Heart Disease, and New-Onset Ventricular Arrhythmia. Journal of the American College of Cardiology 45:9, 1474-1481
CrossRef158
Gerald V. Naccarelli, Mary Ann Lukas. (2005) Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction. Clinical Cardiology 28:4, 165-173
CrossRef159
C. Nelson, T. H. Marwick. (2005) Clinical decision-making and myocardial viability: current perspectives. Internal Medicine Journal 35:2, 118-125
CrossRef160
MICHAEL O. SWEENEY, MARK H. SCHOENFELD, DAVID S. CANNOM. (2005) Rules of Evidence:. CMS and Primary Prevention of Sudden Cardiac Death in Systolic Heart Failure. Pacing and Clinical Electrophysiology 28:2, 81-88
CrossRef161
Bardy, Gust H., Lee, Kerry L., Mark, Daniel B., Poole, Jeanne E., Packer, Douglas L., Boineau, Robin, Domanski, Michael, Troutman, Charles, Anderson, Jill, Johnson, George, McNulty, Steven E., Clapp-Channing, Nancy, Davidson-Ray, Linda D., Fraulo, Elizabeth S., Fishbein, Daniel P., Luceri, Richard M., Ip, John H., . (2005) Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. New England Journal of Medicine 352:3, 225-237
Full Text162
Sergio Richter, Gabor Duray, Gerian Grönefeld, Carsten W Israel, Stefan H Hohnloser. (2005) Prevention of Sudden Cardiac Death. Circulation Journal 69:6, 625-629
CrossRef163
Sanjeev Saksena. (2005) Federal Guidelines for Prophylactic ICD Therapy in High Risk Populations for Sudden Cardiac Death: Is this a Necessary Course Correction?. Journal of Interventional Cardiac Electrophysiology 12:1, 5-7
CrossRef164
Mamoru Hase, Kazufumi Tsuchihashi, Noriyuki Fujii, Kimio Nishizato, Nobuaki Kokubu, Satoshi Nara, Yoshihiko Kurimoto, Akiyoshi Hashimoto, Kikuya Uno, Tetsuji Miura, Nobuyuki Ura, Yasufumi Asai, Kazuaki Shimamoto. (2005) Early Defibrillation and Circulatory Support Can Provide Better Long-Term Outcomes Through Favorable Neurological Recovery in Patients With Out-of-Hospital Cardiac Arrest of Cardiac Origin. Circulation Journal 69:11, 1302-1307
CrossRef165
Hohnloser, Stefan H., Kuck, Karl Heinz, Dorian, Paul, Roberts, Robin S., Hampton, John R., Hatala, Robert, Fain, Eric, Gent, Michael, Connolly, Stuart J., . (2004) Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction. New England Journal of Medicine 351:24, 2481-2488
Full Text166
Kumaraswamy Nanthakumar, Andrew E. Epstein, G. Neal Kay, Vance J. Plumb, Douglas S. Lee. (2004) Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology 44:11, 2166-2172
CrossRef167
Wojciech Zareba. (2004) Implantable cardioverter defibrillator therapy in postinfarction patients. Current Opinion in Cardiology 19:6, 619-624
CrossRef168
Leonard I. Ganz. (2004) Primary prevention of sudden cardiac death. Current Cardiology Reports 6:5, 339-347
CrossRef169
Lydia A. Conlay. (2004) Special Concerns in the Cardiac Catheterization Lab. International Anesthesiology Clinics 41:2, 63-67
CrossRef170
Sri Sundaram, Jeffrey J. Goldberger. (2004) Risk stratification and epidemiology of sudden death. Current Cardiology Reports 6:5, 333-338
CrossRef171
Abrar H. Shah, David T. Huang, Spencer Z. Rosero, James P. Daubert. (2004) Update on implantable cardioverter defibrillator trials. Current Cardiology Reports 6:5, 327-332
CrossRef172
LEONARD GANZ. (2004) Mechanisms of Ventricular Tachycardia Induction. Journal of Cardiovascular Electrophysiology 15:8, 908-910
CrossRef173
Gerald V Naccarelli. (2004) Implantable cardioverter-defibrillators: expanding indications. Current Opinion in Cardiology 19:4, 317-322
CrossRef174
Lynda L. Mickleborough, Naeem Merchant, Joan Ivanov, Vivek Rao, Susan Carson. (2004) Left ventricular reconstruction: Early and late results. The Journal of Thoracic and Cardiovascular Surgery 128:1, 27-37
CrossRef175
T. J. Bunch, R. D. White, B. J. Gersh, W.-K. Shen, S. C. Hammill, D. L. Packer. (2004) Outcomes and In-hospital Treatment of Out-of-Hospital Cardiac Arrest Patients Resuscitated From Ventricular Fibrillation by Early Defibrillation. Mayo Clinic Proceedings 79:5, 613-619
CrossRef176
Chandra Kunavarapu, Daniel M. Bloomfield. (2004) Role of noninvasive studies in risk stratification for sudden cardiac death. Clinical Cardiology 27:4, 192-197
CrossRef177
J. Jason Sims, Michael R. Ujhelyi. (2004) Better Living Through Medical Device Technology. Pharmacotherapy 24:2, 298-306
CrossRef178
Dulce Obias-Manno, Mevan Wijetunga. (2004) Risk Stratification and Primary Prevention of Sudden Cardiac Death. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 15:3, 404-418
CrossRef179
DiMarco, John P., . (2003) Implantable Cardioverter–Defibrillators. New England Journal of Medicine 349:19, 1836-1847
Full Text180
Michiel J. Janse. (2003) A brief history of sudden cardiac death and its therapy. Pharmacology & Therapeutics 100:1, 89-99
CrossRef181
N. Marczin, N. El-Habashi, D. Royston. (2003) Free radicals and cardiac arrhythmias following coronary surgery: actors of the drama or bystanders of the spectacle?. Acta Anaesthesiologica Scandinavica 47:6, 639-642
CrossRef182
Lynda L Mickleborough, Naeem Merchant, Yves Provost, Susan Carson, Joan Ivanov. (2003) Ventricular reconstruction for ischemic cardiomyopathy. The Annals of Thoracic Surgery 75:6, S6-S12
CrossRef183
Thomas F. Oppelt, Rodel V. Bobadilla. (2003) Better Living Through Chemistry: Does It Still Apply to Patients After Myocardial Infarction?. Pharmacotherapy 23:6, 816-822
CrossRef184
Bruce W. Lytle. (2003) The role of coronary revascularization in the treatment of ischemic cardiomyopathy. The Annals of Thoracic Surgery 75:6, S2-S5
CrossRef185
S.Adam Strickberger, John D Hummel, Thomas G Bartlett, Howard I Frumin, Claudio D Schuger, Scott L Beau, Cynthia Bitar, Fred Morady. (2003) Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia—AMIOVIRT. Journal of the American College of Cardiology 41:10, 1707-1712
CrossRef186
Anne M. Gillis, Robert S. Sheldon, D. George Wyse, Henry J. Duff, Margaret R. Cassidy, L. Brent Mitchell. (2003) Clinical and Electrophysiologic Predictors of Ventricular Tachyarrhythmia Recurrence in Patients with Implantable Cardioverter Defibrillators. Journal of Cardiovascular Electrophysiology 14:5, 492-498
CrossRef187
Douglas S Lee, Lawrence D Green, Peter P Liu, Paul Dorian, David M Newman, F.Curry Grant, Jack V Tu, David A Alter. (2003) Effectiveness of implantable defibrillators for preventing arrhythmic events and death. Journal of the American College of Cardiology 41:9, 1573-1582
CrossRef188
Peter Lercher, Brigitte Rotman, Daniel Scherr, Wilfried Kraxner, Olef Luha, Werner Klein. (2003) Die Auswirkungen nach dem Multicenter Automatic Defibrillator Implantation Trial II in einem kardiologischen Schwerpunktzentrum — müssen alle Postinfarktpatienten mit reduzierter Linksventrikelfunktion einen implantierbaren Kardioverter-Defibrillator erhalten?. Wiener Klinische Wochenschrift 115:5-6, 167-174
CrossRef189
Wolfram Grimm, Julia Liedtke, Hans-Helge Muller. (2003) Prevalence of Potential Noninvasive Arrhythmia Risk Predictors in Healthy, Middle-Aged Persons. Annals of Noninvasive Electrocardiology 8:1, 37-46
CrossRef190
Michael E. Bourke, Jeffrey S. Healey. (2002) Pacemakers, recent directions and developments. Current Opinion in Anaesthesiology 15:6, 681-686
CrossRef191
Abeel A Mangi, Theodore J Boeve, Gus J Vlahakes, Cary W Akins, Alan D Hilgenberg, Jeremy N Ruskin, Brian M McGovern, David F Torchiana. (2002) Surgical coronary revascularization and antiarrhythmic therapy in survivors of out-of-hospital cardiac arrest. The Annals of Thoracic Surgery 74:5, 1510-1516
CrossRef192
Gabriel Gregoratos, Jonathan Abrams, Andrew E Epstein, Roger A Freedman, David L Hayes, Mark A Hlatky, Richard E Kerber, Gerald V Naccarelli, Mark H Schoenfeld, Michael J Silka, Stephen L Winters, Raymond J Gibbons, Elliott M Antman, Joseph S Alpert, Gabriel Gregoratos, Loren F Hiratzka, David P Faxon, Alice K Jacobs, Valentin Fuster, Sidney C Smith. (2002) ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—Summary Article. Journal of the American College of Cardiology 40:9, 1703-1719
CrossRef193
Avi A. Weinbroum, Aharon Glick, Yitzchak Copperman, Tamar Yashar, Valery Rudick, Ron Flaishon. (2002) Halothane, Isoflurane, and Fentanyl Increase the Minimally Effective Defibrillation Threshold of an Implantable Cardioverter Defibrillator: First Report in Humans. Anesthesia & Analgesia 95:5, 1147-1153
CrossRef194
B. John Hynes, Jerry C. Luck, Deborah L. Wolbrette, John Boehmer, Gerald V. Naccarelli. (2002) Arrhythmias in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 4:6, 467-485
CrossRef195
Johan De Sutter, Vida Firsovaite, Rene Tavernier. (2002) Prevention of Sudden Death in Patients With Coronary Artery Disease: Do Lipid-Lowering Drugs Play a Role?. Preventive Cardiology 5:4, 177-182
CrossRef196
Carmine A. Sorbera, Evelyn J. Cusack. (2002) Indications for Implantable Cardioverter Defibrillator Therapy. Heart Disease 4:3, 166-170
CrossRef197
Bigger, J. Thomas, . (2002) Expanding Indications for Implantable Cardiac Defibrillators. New England Journal of Medicine 346:12, 931-933
Full Text198
Alan Kadish. (2002) Primary prevention ofsudden death using ICD therapy: incremental steps. Journal of the American College of Cardiology 39:5, 788-789
CrossRef199
K. Hnatkova, S. J. Ryan, J. Bathen, H. H. Hoium, M. Malik. (2002) Non-invasive Wedensky modulation within the QRS complex. Medical & Biological Engineering & Computing 40:2, 234-240
CrossRef200
Jan P. Amlie, S. Bertil Olsson. (2002) Should we Implant ICDs in More Patients after Myocardial Infarction? Can we Define the Patient Groups that Benefit Most?. Scandinavian Cardiovascular Journal 36:5, 259-261
CrossRef201
David S. Cannom. (2002) Implantable cardioverter defibrillator trials: what's new?. Current Opinion in Cardiology 17:1, 29-35
CrossRef202
Jan Erik Otterstad, Keith A. A. Fox. (2002) Clinical Implications of CURE and PCI-CURE in Patients with the Acute Coronary Syndrome without Persistent ST-elevation. Scandinavian Cardiovascular Journal 36:5, 261-271
CrossRef203
McNeil, Barbara J., . (2001) Hidden Barriers to Improvement in the Quality of Care. New England Journal of Medicine 345:22, 1612-1620
Full Text204
Huikuri, Heikki V., Castellanos, Agustin, Myerburg, Robert J., . (2001) Sudden Death Due to Cardiac Arrhythmias. New England Journal of Medicine 345:20, 1473-1482
Full Text205
STEVEN E. LIPSHULTZ, STACY D. FISHER, WYMAN W. LAI, TRACIE L. MILLER. (2001) Cardiovascular Monitoring and Therapy for HIV-Infected Patients. Annals of the New York Academy of Sciences 946:1, 236-273
CrossRef206
Christoph Scharf, Hermann Redecker, Firat Duru, Reto Candinas, Hans Peter Brunner-La Rocca, Andreas Gerber, Osmund Bertel, Marko I Turina, Wolfgang Kiowski. (2001) Sudden cardiac death after coronary artery bypass grafting is not predicted by signal-averaged ECG. The Annals of Thoracic Surgery 72:5, 1546-1551
CrossRef207
P. Göudde, R. Agrawal, H.-P. Müuller, K. Czerski, P. Endt, U. Steinhoff, M. Oeff, H.-P. Schultheiss, S. Behrens. (2001) Magnetocardiographic mapping of QRS fragmentation in patients with a history of malignant tachyarrhythmias. Clinical Cardiology 24:10, 682-688
CrossRef208
Nabil El-Sherif, Gioia Turitto, Ronald P. Pedalino, Dyonissios Robotis. (2001) T-Wave Alternans and Arrhythmia Risk Stratification. Annals of Noninvasive Electrocardiology 6:4, 323-332
CrossRef209
John P DiMarco. (2001) Is programmed stimulation in survivors of myocardial infarction helpful?. Journal of the American College of Cardiology 37:7, 1908-1909
CrossRef210
Claus Schmitt, Petra Barthel, Gjin Ndrepepa, Jürgen Schreieck, Andreas Plewan, A Schömig, Georg Schmidt. (2001) Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. Journal of the American College of Cardiology 37:7, 1901-1907
CrossRef211
Gillian D. Sanders, Robert F. Nease, Douglas K. Owens. (2001) Publishing web-based guidelines using interactive decision models. Journal of Evaluation in Clinical Practice 7:2, 175-189
CrossRef212
Daniel E. Hilleman, Jerry L. Bauman. (2001) Role of Antiarrhythmic Therapy in Patients at Risk for Sudden Cardiac Death: An Evidence-Based Review. Pharmacotherapy 21:5, 556-575
CrossRef213
Robert W. Peters, Michael R. Gold. (2001) Implantable Cardiac Defibrillators. Medical Clinics of North America 85:2, 343-367
CrossRef214
MARK H. SCHOENFELD. (2000) Deciding Against Defibrillator Replacement: Second-Guessing the Past?. Pacing and Clinical Electrophysiology 23:12, 2019-2021
CrossRef215
MICHAEL GEIST, DAVID NEWMAN, MARY GREENE, MINEY PAQUETTE, PAUL DORIAN. (2000) Permanent Explantation of Implantable Cardioverter Defibrillators. Pacing and Clinical Electrophysiology 23:12, 2024-2029
CrossRef216
Michael R Gold, Daniel M Bloomfield, Kelley P Anderson, Nabil E El-Sherif, David J Wilber, William J Groh, N.A.Mark Estes, Elizabeth S Kaufman, Mark L Greenberg, David S Rosenbaum. (2000) A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. Journal of the American College of Cardiology 36:7, 2247-2253
CrossRef217
Hal V Barron. (2000) T-wave alternans and serious ventricular arrhythmias: a tale of two T-waves. Journal of the American College of Cardiology 36:7, 2254-2256
CrossRef218
Jeffrey J Goldberger, Suresh Neelagaru. (2000) Therapeutic developments in sudden cardiac death. Expert Opinion on Investigational Drugs 9:11, 2543-2554
CrossRef219
Mina K. Chung. (2000) Cardiac surgery: Postoperative arrhythmias. Critical Care Medicine 28:Supplement, N136-N144
CrossRef220
William Whang, J.Thomas Bigger. (2000) Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. Journal of the American College of Cardiology 36:4, 1166-1172
CrossRef221
Johan De Sutter, Rene Tavernier, Marc De Buyzere, Luc Jordaens, Guy De Backer. (2000) Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. Journal of the American College of Cardiology 36:3, 766-772
CrossRef222
Peter A. O'Callaghan. (2000) Prophylactic defibrillator implantation in patients with coronary artery disease. Current Cardiology Reports 2:4, 311-313
CrossRef223
Michael J. Domanski. (2000) Prevention of sudden cardiac death: management considerations. Current Opinion in Cardiology 15:4, 304-308
CrossRef224
XAVIER COPIE, OLIVIER PIOT, MINA AIT SAID, THOMAS LAVERGNE, JACKY OLLITRAULT, LOUIS GUIZE, JEAN-YVES HEUZEY, . (2000) Temporal and Geographical Trends in Indications for Implantation of Cardiac Defibrillators in Europe 1993-1998. Pacing and Clinical Electrophysiology 23:6, 979-984
CrossRef225
ALFRED P. HALLSTROM, JEFFREY L. ANDERSON, LEONARD A. COBB, PETER L. FRIEDMAN, JOHN M. HERRE, RICHARD C. KLEIN, JOHN MCANULTY, JONATHAN S. STEINBERG, . (2000) Advantages and Disadvantages of Trial Designs: A Review of Analysis Methods for ICD Studies. Pacing and Clinical Electrophysiology 23:6, 1029-1038
CrossRef226
H. Leon Greene. (2000) The implantable cardioverter-defibrillator. Clinical Cardiology 23:5, 315-326
CrossRef227
Jennifer A. Larsen, Alan H. Kadish, Janice B. Schwartz. (2000) Proper Use of Antiarrhythmic Therapy for Reduction of Mortality After Myocardial Infarction. Drugs & Aging 16:5, 341-350
CrossRef228
Douglas P. Zipes. (2000) A century of cardiac arrhythmias. Journal of the American College of Cardiology 35:5, 38B-44B
CrossRef229
Vend Menon, Jonathan S. Steinberg, Luis Carillo, Toshio Akiyama, Karen Beckman, Steven Kutalek. (2000) Implantable cardioverter defibrillator discharge rates in patients with unexplained syncope, structural heart disease, and inducible ventricular tachycardia at electrophysiologic study. Clinical Cardiology 23:3, 195-200
CrossRef230
NEAL G. KAVESH, SAMANTHA E. SARANG, MICHAEL R. GOLD. (2000) Signal-Averaged Isoharmonic Body Surface Maps of Patients with Ischemic Cardiomyopathy. Journal of Cardiovascular Electrophysiology 11:2, 160-167
CrossRef231
Gerald V. Naccarelli, Deborah L. Wolbrette, Joseph T. Dell'Orfano, Hemantkumar M. Patel, Jerry C. Luck. (2000) Amiodarone: What have we learned from clinical trials?. Clinical Cardiology 23:2, 73-82
CrossRef232
M. Abdelnoor, S. Nitter-Hauge, Ø. R. (2000) Duration of Preoperative Electrocardiographic QRS Complex and the Incidence of Heart Arrest after Aorto Coronary Bypass Surgery. Scandinavian Cardiovascular Journal 34:2, 186-191
CrossRef233
Franco Naccarella, Giovannina Lepera, Angelo Rolli. (2000) Arrhythmic risk stratification of post–myocardial infarction patients. Current Opinion in Cardiology 15:1, 1-6
CrossRef234
LARS ECKARDT, WILHELM HAVERKAMP, ROBERT JOHNA, DIRK BÖCKER, MARIO C. DENG, GÜNTER BREITHARDT, MARTIN BORGGREEE. (2000) Arrhythmias in Heart Failure:.. Journal of Cardiovascular Electrophysiology 11:1, 106-117
CrossRef235
CRAIG M. PRATT, A. JOHN CAMM, J. THOMAS BIGGER, GÜNTER BREITHARDT, RONALD W.F. CAMPBELL, ANDREW E. EPSTEIN, LUKAS J. KAPPENBERGER, KARL-HEINZ KUCK, STUART POCOCK, SANJEEV SAKSENA, ALBERT L. WALDO. (1999) Evaluation of Antiarrhythmic Drug Efficacy in Patients with an ICD:.. Journal of Cardiovascular Electrophysiology 10:11, 1534-1549
CrossRef236
Ryszard B. Krol, Sanjeev Saksena, Atul Prakash. (1999) Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias. Current Cardiology Reports 1:4, 282-288
CrossRef237
Kelley P. Anderson, Vladimir Shusterman, Susan Brode, Venkateshwar Gottipaty, David Schwartzman, Raul Weiss. (1999) Noninvasive Testing for Selection of Patients for Electrophysiological Study. Annals of Noninvasive Electrocardiology 4:4, 434-442
CrossRef238
Patrick J Welch, Richard L Page, Mohamed H Hamdan. (1999) Management of ventricular arrhythmias. Journal of the American College of Cardiology 34:3, 621-630
CrossRef239
PEARILA B. NAMEROW, BEVERLY R. FIRTH, GEOFFREY M. HEYWOOD, JOHN R. WINDLE, MICHAEL K. PARIDES, . (1999) Quality-of-Life Six Months After CABG Surgery in Patients Randomized to ICD Versus No ICD Therapy: Findings from the CABG Patch Trial. Pacing and Clinical Electrophysiology 22:9, 1305-1313
CrossRef240
Jeffrey N. Rottman, Bruce Levin, Myunghee Cho Paik, Wei Yann Tsai, J. Thomas Bigger, . (1999) Using missing data techniques to explore the lack of survival effect: illustration with the CABG patch trial. Statistics in Medicine 18:15, 1943-1959
CrossRef241
Ted C Braun, Neil A Hagen, Robert E Hatfield, D.George Wyse. (1999) Cardiac Pacemakers and Implantable Defibrillators in Terminal Care. Journal of Pain and Symptom Management 18:2, 126-131
CrossRef242
Jeffrey J. Goldberger. (1999) Sudden cardiac death. Current Treatment Options in Cardiovascular Medicine 1:2, 127-135
CrossRef243
Eugene Crystal, I. Eli Ovsyshcher. (1999) Letters to the Editor. Journal of Cardiovascular Electrophysiology 10:3, 420-421
CrossRef244
Gerald V. Naccarelli, Deborah L. Wolbrette, Joseph T. Dell'Orfano, Hemantkumar M. Patel, Jerry C. Luck. (1999) Reply to the Editor. Journal of Cardiovascular Electrophysiology 10:3, 421-421
CrossRef245
RAYMOND YEE, STUART J. CONNOLLY, ANNE M. GILLIS. (1999) Appropriate Use of the Implantable Cardioverter Defibrillator: A Canadian Perspective. Pacing and Clinical Electrophysiology 22:1, 1-4
CrossRef246
Peter Weismüller, Hans-Joachim Trappe. (1999) Update Kardiologie. Medizinische Klinik 94:1, 15-28
CrossRef247
Craig A. Swygman, Munther K. Homoud, Mark S. Link, Paul J. Wang, N. A. Mark Estes. (1999) Technologic advances in implantable cardioverter defibrillators. Current Opinion in Cardiology 14:1, 9
CrossRef248
STEFAN H. HOHNLOSER, THOMAS KLINGENHEBEN, YI-GANG LI, MARKUS ZABEL, JOY PEETERMANS, RICHARD J. COHEN. (1998) T Wave Alternans as a Predictor of Recurrent Ventricular Tachyarrhythmias in ICD Recipients: Prospective Comparison with Conventional Risk Markers. Journal of Cardiovascular Electrophysiology 9:12, 1258-1268
CrossRef249
CHARLES GOTTLIEB, DAVID J. CALLANS, FRANCIS MARCHLINSKI. (1998) Implantable Cardioverter Defibrillators in the United States: Understanding the Benefits and Limitations of Implantable Cardioverter Defibrillator Therapy Based on Clinical Trial Results. Pacing and Clinical Electrophysiology 21:11, 2016-2020
CrossRef250
Wolfram Grimm, Jürgen Hoffmann, Volker Menz, Kathrin Luck, Bernhard Maisch. (1998) Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. Journal of the American College of Cardiology 32:3, 739-745
CrossRef251
GERALD V. NACCARELLLI, DEBORAH L. WOLBRETTE, JOSEPH T. DELL'ORFANO, HEMANTKUMAR M. PATEL, JERRY C. LUCK. (1998) A Decade of Clinical Trial Developments in Postmyocardial Infarction, Congestive Heart Failure, and Sustained Ventricular Tachyarrhythmia Patients: From CAST to AVID and Beyond. Journal of Cardiovascular Electrophysiology 9:8, 864-891
CrossRef252
Stuart J Connolly. (1998) Implantable cardioverter defibrillators—for whom?. The Lancet 352:9125, 338-340
CrossRef253
John GF Cleland, Karl Swedberg, Philip A Poole-Wilson. (1998) Successes and failures of current treatment of heart failure. The Lancet 352, SI19-SI28
CrossRef254
W Groh. (1998) The use of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. ACC Current Journal Review 7:4, 48-51
CrossRef255
SEAH NISAM, MORTON MOWER. (1998) ICD Trials: An Extraordinary Means of Determining Patient Risk?. Pacing and Clinical Electrophysiology 21:7, 1341-1346
CrossRef256
NEAL G. KAVESH, STEPHEN R. SHOROFSKY, SAMANTHA E. SARANG, MICHAEL R. GOLD. (1998) Effect of Heart Rate on T Wave Alternans. Journal of Cardiovascular Electrophysiology 9:7, 703-708
CrossRef257
SEAH NISAM, IGOR SINGER. (1998) Prophylactic Trials With Implantable Cardioverter Defibrillators: MADIT and Beyond. Journal of Interventional Cardiology 11:3, 227-233
CrossRef258
DAVID S. CANNOM. (1998) AVID and Beyond: Lessons Learned. Journal of Interventional Cardiology 11:3, 217-226
CrossRef259
L. BRENT MITCHELL. (1998) Pharmacological Therapy for Ventricular Arrhythmias in the Era of the Implantable Cardioverter Defibrillator: Indispensable or Inadvisable?. Journal of Interventional Cardiology 11:3, 235-246
CrossRef260
(1998) Prophylactic Use of Implanted Cardiac Defibrillators in Patients at High Risk for Ventricular Arrhythmias after Coronary-Artery Bypass Graft Surgery. New England Journal of Medicine 338:17, 1227-1228
Full Text261
Eleanor B Schron, Lawrence M Friedman, H Leon Greene, Chuke Nwachuku. (1998) Ongoing and planned clinical trials of anti-arrhythmic drugs: an update. Expert Opinion on Investigational Drugs 7:3, 427-435
CrossRef262
Hal V Barron, Sami Viskin. (1998) Autonomic markers and prediction of cardiac death after myocardial infarction. The Lancet 351:9101, 461-462
CrossRef263
Myerburg, Robert J., Castellanos, Agustin, . (1997) Clinical Trials of Implantable Defibrillators. New England Journal of Medicine 337:22, 1621-1623
Full Text
- Letters
